BioCentury
ARTICLE | Finance

Picking season

Why small- and mid-cap biotechs will remain in vogue in 2Q18

April 6, 2018 10:51 PM UTC

Macroeconomic risks, surging volatility and a tail-off in the M&A market since January have done little to change the buyside’s strategy of overweighting small- and mid-cap biotechs.

In fact, the 12 investors who spoke to BioCentury are reveling under conditions they say favor stock picking and allow for meaningful alpha generation, or outperformance of the sector benchmarks. Moreover, they expect the conditions to persist at least through the second quarter and perhaps the rest of the year...